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ABSTRACT 
Objective: The objective of present work was to develop and validate simple, precise, accurate and specific stability indicating method for 
determination of nepafenac in presence of its degradation products and application of the method to study degradation kinetics.  
Methods: A novel isocratic RP-HPLC method has been developed using C8Olyster column, (250X4.6 mm i. d, 5µ particle size) with the mobile phase 
composition of ACN: 10 mM Ammonium formate buffer (pH 4.0): Methanol (27.5:45:27.5). The flow rate was at 1.0 ml min-1
Results: The degradants peaks were well resolved from Nepafenac peak. Significant degradation was observed in acid, base and oxidative 
degradation. The drug is relatively stable towards photolysis and dry heat. 
 and effluent was 
detected at 238 nm. Nepafeac was subjected to stress degradation under acid, base, neutral hydrolysis, oxidation, dry heat, humidity and photolysis, 
conditions. Kinetic study was also performed. 
Conclusion: Stability of Nepafenac was determined by stability indicating assay method. Three degradation related impurities was identified by LC-
MS. The hydrolytic degradation pathway of nepafenac was postulated. The developed stability indicating method was applied to determine acid, 
base and oxidative degradation kinetic. Acid hydrolysis and oxidative degradation followed zero order while base hydrolysis followed first order 
kinetic. Degradation rate constants and half-life were determined. 
Keywords: Nepafenac, Reverse Phase High Performance Liquid Chromatography (RP-HPLC), Stability Indicating Assay Methods (SIAM’S), Stress 
Degradation, ICH Q1A (R2), Q2 R1.  
 
INTRODUCTION 
Nepafenac (NEPA), [2-(2-amino 3-benzoyl phenyl) acetamide] (II, 
Fig. 1) is antiinflammatory (NSAID’s) which is indicated for the 
treatment of pain and inflammation associated with cataract 
surgery. NEPA is a pro drug. After penetrating the cornea, NEPA 
undergoes rapid bioactivation to amfenac, which is a potent NSAID 
that uniformly inhibits the COX1 and COX2 activity [1]. Amfenac is 
thought to inhibit the action of prostaglandin H synthase 
(cyclooxygenase), an enzyme required for prostaglandin production. 
Preparation of NEPA is disclosed in US patent 4313947 and the 
scheme is depicted in Fig. 1[2]. 
 
 
I=NEPA, II= 2-amino-benzophenone,III=2-Methylsulfanyl-acetamide, 
IV= 2-amino-3-benzoyl-α-(methylthio)-benzeneacetamide 
Fig. 1: Synthetic Scheme of NEPA 
 
There is always need for significant SIM’S in modern analytical labs. 
Environmental factors, such as the temperature, pH,buffer species, 
ionic strength, light, oxygen, moisture, additives and excipients, can 
play an important role in the stability of drug substances. Stress 
testing can help in identifying degradationproducts and provide 
important information about the intrinsic stability of drug 
substances [3]. Stability indicating assay is defined as a validated 
quantitativeanalytical procedure that can detect the changes with 
time in the pertinent properties (e. g., active ingredient, preservative 
level) of the drug substance and drug product. A stability-indicating 
assayaccuratelymeasures the active ingredients without 
interferencesfrom degradation products, process impurities, excipients, 
or other potential impurities [4]. No official USP (United States 
Pharmacopeia Convention) andEP (European Pharmacopoeia) 
monographs currently exist for NEPA. The literature survey reveals that. 
Two simple and sensitive visible spectrophotometric methods have been 
developed for the estimation of NEPA in pure and pharmaceutical 
dosage forms [5,6]. Determination of NEPA in plasma by RP-HPLC has 
also been reported [7]. Method for determining chemical purity of NEPA 
by High performance liquid chromatography with ultraviolet visible 
detector(HPLC-UV)was disclosed in patent document [8]. The method 
utilizes gradient elution using mobile phase Ammonium formate buffer 
(PH 4.25 with formic acid) and acetonitrile (ACN). The separation was 
carried out on C-18 column. The chromatographic run time was at least 
65 min. HPLC-UV studies of the chemical purity or assay of the NEPA 
was also reported by ElzbietaLipiec-Abramska et al.[9]As in patent 
document, the method also utilizes gradient elution with mobile 
phase ammonium formate (pH 4.10 ± 0.02 adjusted with formic 
acid) and ACN using C18 column at a column temperature of 300
MATERIALS AND METHODS 
C. 
But the chromatographic run time is 29 min. Hence, the main 
objective of our work was to develop a simple, accurate and precise, 
stability-indicating HPLC-UV method for determination of NEPA and 
its degradation products within a short run time. In contrast to the 
above reported HPLC-UV methods, the chromatographic run time of 
the present method is 12 min with isocratic elution. Stress 
degradation was also performed to determine the most potential 
degradation related impurities. The validated method was applied to 
study the rate of degradation of NEPA under acid, base hydrolysis 
and oxidative degradation. 
Chemicals, Reagents and Solutions 
NEPA (Bulk drug) and impurities were kindly provided by Sun 
Pharmaceuticals. Baroda and were used as received. Nevanac 
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Ophthalmic suspension 0.1%w/v (Alcon, USA) was purchased from 
local pharmacy. HPLC grade Methanol (MeOH) and ACN were 
purchased from Rankem Ltd, Mumbai. HPLC grade Ammonium 
Formate and formic acid were purchased from LobaChemie Pvt Ltd, 
Mumbai. Analytical grade Hydrochloricacid (HCl), sodium hydroxide 
(NaOH), and hydrogen peroxide (H2O2)were purchased from S D 
FineChem. Ltd. Mumbai, India. A 10 mM Ammonium Formate buffer 
was prepared by dissolving 0.6306 g of Ammonium Formate in 
sufficient water to produce 1000 ml, and then the pH 4.0 was 
adjusted with Formic acid.  
Instrumentation and Chromatographic Conditions 
HPLC-UV 
Analytical Chromatography was performed on Shimadzu (Shimadzu 
Corporation, Kyoto, Japan) chromatographic system equipped with 
Shimadzu LC-20AT pump and Shimadzu SPD-20AV absorbance 
detector. Samples were injected through a Rheodyne 7725 injector 
valve with fixed loop at 20 μl. Data acquisition and integration was 
performed using Spinchrome software (Spincho biotech, Vadodara). 
Chromatographic separation of NEPA was achieved at ambient 
temperature using C-8 Olyster column (250 X 4.6 mm i. d., 5 µ 
particle size) with mobile phase composition of ACN: 10 mM 
Ammonium Formate buffer (pH 4.0 adjusted with formic acid): 
MeOH (27.5:45:27.5). The flow rate was at 1.0 ml min-1at ambient 
column temperature and effluent was detected at 238 nm. Before 
use, the mobile phase was filtered through a 0.2 µ nylon membrane 
filter and sonicated for 5 min.  
Construction of the calibration curve 
NEPA stock solution (1mg mL-1) was prepared by dissolving 25 mg 
of NEPA in 25 ml MeOH in 25 ml volumetric flask. NEPA working 
solution (0.1 mg mL-1) was prepared by transferring 2.5 ml from 
stock solution to 25 ml volumetric flask and diluted up to the mark 
with MeOH. Aliquots ranging from 0.01 ml to 2 ml were taken, from 
standard stock solution, in 10 ml volumetric flask and diluted to 10 
ml with Mobile phase to give final concentration of 1, 5, 10, 25, 50, 
75, 100, 150 & 200 μg mL-1
An LC–MS system (Thermo Scientific, Sunnyvale, CA, USA) 
comprised of a LCQ Fleet Ion Trap Mass Spectrometer. The analysis 
was performed in positive electro-spray/positive ionization mode 
with an ion source voltage of 5000 V and a source temperature of 
450
 of NEPA. 20 μl of each concentration 
were injected in the chromatographic system and chromatogram 
was recorded. Calibration graph was constructed by plotting peak 
area versus concentration of each drug and the regression equation 
was calculated. 
LC-MS (Liquid Chromatography –Mass Spectroscopy) 
0
Forced Degradation Study 
C. The curtain gas flow was 20 psi. The data was collected and 
processed using Surveyor plus HPLC System with Qual browser 
software. Column, mobile phase, flow rate and column temperature 
were same as in HPLC-UV.  
Hydrolytic conditions 
Acid, alkali and water induced degradation 
10 mg of API & ophthalmic suspension (equivalent to 10 mg 
NEPA)were taken in 10 ml volumetric flasks separately, 4 ml of 
MeOHwas added to dissolved the API and sonicated for 3 min. 0.01N 
HCL,1N NaOH and Waterwere added separately to make up the 
volume and subjected to the conditions specified in table1. 
Degradation was performed in the dark in order to exclude possible 
degradation effect of light. 
Oxidizing conditions 
hydrogen peroxide-induced degradation 
10 mg of API & ophthalmic suspension (equivalent to 10 mg NEPA) 
were taken 10 ml volumetric flask, 5 ml of MeOH added & sonicated 
then volume was made with 30 % H2O2
Thermal conditions 
dry heat  
API and ophthalmic suspension (equivalent to 10 mg NEPA) were 
placed in an oven at 80ºC for 7 days under dry heat condition in the 
dark and then cooled to room temperature.  
Photolytic degradation 
For the photochemical stability API and ophthalmic suspension 
(equivalent to 10 mg NEPA) was spread in 1 mm thickness on a 
petridish and exposed to 5382 LUX and 144UW/cm
. The solution was 
transferred to RBF and subjected to the conditions specified in 
table1. 
2 
The sample from acid and base induced degradation was neutralized 
by adding appropriate strength of NaOH/formic acid. All samples 
were stored at 2–8 
for 8 days.  
Thermal & Humidity 
API and ophthalmic suspension (equivalent to 10 mg NEPA) was 
placed in Stability Chamber at 40ºC±2º C and 75±5 % RH for 15 
days. 
Sample collection, storage and preparation 
0
 
C in the refrigerator. On theday of analysis 
samples were diluted with the mobile phaseto make the final 
concentrationof 100 µg/ml in all conditions, filtered with a 0.22 µm 
membrane syringe filterand injected three times for each sample 
into HPLC. 
Table 1: Stress conditions for forced degradation study of Nepafenac 






MeOH, 0.01N HCl 



















Thermal & Humidity  40ºC±2 ºC & 75% RH 336 
Photolytic -- 5382 LUX and 144UW/cm 192 2 
 
RESULTS AND DISCUSSION 
Method Development and Optimization 
A detection wavelength 238 nm was selected from the full range UV 
spectral data due to its high sensitivity for all degradation products 
and minimal difference in response factors. NEPA having pKa (SA) 
15.82 and pKa (SB) 1.83, pH 4.0 buffer was selected to enable better 
column performance. Isocratic run was accessed using mobile phase 
10 mM Ammonium formate buffer pH 4.0: ACN: MeOH 
(45:27.5:27.5) (v/v/v) on C8 and C18 columns. The C8 column 
provided the highest number of peaks and better resolution. Thus, 
further experiments were carried out using anOlyster C8 column.  
Forced Degradation Study 
The results from the stress testing studies indicate the method is 
highly specific for NEPA. Degradation products were completely 
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distinguishable from the parent compound. The drug undergoes 
significant degradation under acid, alkaline and oxidative condition. 
Acidic degradation was faster than basic & oxidative degradation. 
Acid hydrolysis resulted in complete degradation of NEPA. Little 
degradation was observed in photolysis. The drug was relatively 
stable in thermal & relative humidity, dry heat and wet heat 
degradation. Three degradation products were obtained at Rt
In acidic hydrolysis degradants peaks were obtained at RT of 3.3, 3.4 
& 5.3 min on heating. In basic hydrolysis & oxidative additional 
degradants peaks were obtained at RT of 4.0 & 5.3 min apart from 
drug peak. Overall NEPA degradants peaks were observed at RT of 
3.3, 3.4, 4.0, 4.9 5.3, 6.3, 9.1. The MS data shows that bifurcated peak 
at 3.3 & 3.4 have same m/z & fragment at 268 & 222.08 respectively. 
This indicates the presence of enantiomer. Results of forced 
degradation study are summarized in table 2.  
 of 3.3, 
4.0 & 5.3. And some additional peaks are at 6.3 & 9.1. During 
experiments, it was found that NEPA Drug has inherent impurity at 
RT 5.29(Fig.2) that increases in stressed conditions and is common 
in all degradation condition. The typical chromatograms from assay 
of stressed samples are shown in Fig.3.  
 
 






















































F:\HPLC REPORTS-29.11.2011\M.Pharm\M.PHARM 2013\CHHAYA\NOV\26 11 13\T4 100PPM
F:\HPLC REPORTS-29.11.2011\M.Pharm\M.PHARM 2013\CHHAYA\NOV\26 11 13\S3  0.01 I1  60MIN  100PPM
F:\HPLC REPORTS-29.11.2011\M.Pharm\M.PHARM 2013\CHHAYA\DEC\28 12 13\MT1  1 TP I4  100PPM 
F:\HPLC REPORTS-29.11.2011\M.Pharm\M.PHARM 2013\CHHAYA\MARCH\19 03 14\M1 0.1N HCL 1HR
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Fig. 3: (a) Separation of all degradants in stressed samples in 
optimized condition. (b) Overlain Chromatograms of acid 
degradation (0.01 N HCl, at room temperature for 30 min, 
Green – API, Black- Market Formulation, Pink- API treated with 
Acid Stressor, Blue- Formulation treated with Acid Stressor (c) 
LC-MS spectra (d) MS Spectra of NEPA degradation product in 
HCl at RT 3.10 (e) MS Spectra of NEPA degradation product in 
HCl at RT 3.2 (f) MS Spectra of NEPA in HCl at RT 4.4 (g) MS 










Fig. 4: Chromatogram of base degradation (1 N NaOH, at room 
temprature for 1 hrs.): (a) Overlain of API & blank: (RT= 4.1, 
4.60 and 5.3 min.), (b) overlain Chromatograph of Ophthalmic 
suspension: Black without treatment & red after treated with 
Base Stressor: degradant (RT= 4.05 and 5.398 min.) (c) LC-MS & 
MS spectra of NEPA degradation product in NaOH at RT 3.79 
 
 
Fig. 5: Overlain Chromatograms of degradation in hydrogen 
peroxide (30 % H2O2
 
, refluxed at 40ºC for 6 hrs.): Pink – API, 
Black- Ophthalmic suspension, Red- API treated with H₂O₂ 
stressor, blue- formulation treated with H₂O₂ stressor (API: 4.6, 
degradant 5.31 & 6.3) 
Fig. 6: Chromatogram of photochemical degradation (8 days) 
 
 
Fig. 7: Chromatograms of dry heat (80°C for 7 days) 
[min.]Time


















F:\HPLC REPORTS-29.11.2011\M.Pharm\M.PHARM 2013\CHHAYA\DEC\19 12 13\ST1 2HR 10PPM 10mM BAM 
F:\HPLC REPORTS-29.11.2011\M.Pharm\M.PHARM 2013\CHHAYA\DEC\19 12 13\SB1 2HR 10PPM 10mM BAM 
[min.]Time














F:\HPLC REPORTS-29.11.2011\M.Pharm\M.PHARM 2013\CHHAYA\JAN\09 01 14\INTRA PRC\SET I\T1 10PPM


















F:\HPLC REPORTS-29.11.2011\M.Pharm\M.PHARM 2013\CHHAYA\NOV\26 11 13\T3 100PPM
F:\HPLC REPORTS-29.11.2011\M.Pharm\M.PHARM 2013\CHHAYA\DEC\28 12 13\MT1  1 TP I4  100PPM 
F:\HPLC REPORTS-29.11.2011\M.Pharm\M.PHARM 2013\CHHAYA\MARCH\27 03 14\T1 I3 15152O2 _6HR
F:\HPLC REPORTS-29.11.2011\M.Pharm\M.PHARM 2013\CHHAYA\MARCH\27 03 14\M1 I3 15152O2 _6HR
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Fig. 8: Chromatograms of Wet heat (80°C for 4 hrs) 
 
 
Fig. 9: Chromatogram of Thermal- Humidity (40°C±2 °C & 75% 
RH for 2 week
 
Table 2: Summary of forced degradation studies and structure of possible degradation products 
Compound RT m/z Fragments Structure Systematic Name 







[2-(2-amino 3-benzoyl phenyl) acetamide] 








H OO  
7-benzoyl-1,3- dihydro-indol-2-one 
IMP-2 3.79, (Base, Oxidative 
Degradation) 













(b)                                          
 
(c) 
Fig. 10: (a) Overlain Chromatogram of NEPA & its Degradation 
Product. (b) Peak purity for NEPA Drug Peak (c) Peak purity for 
major degradation Peak in HCl 
 
Method Validation 
Linearity and range 
The linearity of proposed HPLC method was evaluated by analyzing 
a series of different concentrations of NEPA (n=11). The linear 
regression equation was generated from calibration data. Under the 
optimized conditions described above, the measured peak areas 
were found to be proportional to concentrations of the analyte 
(Table 3).  
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Fig. 11: Calibration curve of NEPA 
 
Detection and quantification limits 
According to the pharmaceutical recommendations, limit of 
detection (LOD) and limit of quantification (LOQ) were determined, 
at signal to noise ratios of 3:1 and 10:1, respectively (Table 3).  
Precision and Accuracy 
The within-day (intra-day) precision and accuracy for the proposed 
method were studied at three concentration levels of NEPA using 
three replicate determinations for each concentration within one 
day. Similarly, the between-day (inter-day) precision and accuracy 
were tested by analyzing the same three concentrations using three 
replicate determinations repeated on three days. Recoveries were 
calculated using the regression equation and they were satisfactory. 
The percentage of relative standard deviation (%RSD) were less 
than 1.5% providing the high repeatability, intermediate precision 
and accuracy of the developed method for the estimation of NEPA in 
bulk form (table 3).  
Robustness 
The robustness was examined by evaluating the influence of small 
variations in different conditions such as flow rate, change in pH of 
buffer, detection wavelengths and organic ratio. The average value 
of % RSD for determination of NEPA less than 2 % revealed the 
robustness of the method. 
Ruggedness 
To evaluate ruggedness of the method few parameters were 
deliberately varied. The parameters included different instruments. 
The average value of % RSD for determination of NEPA less than 2 % 
revealed the ruggedness of the method. 
Stability of solutions 
Solutions containing different concentrations of NEPA were 
prepared from standard stock solution and stored at room 
temperature for 24 hrs. They were then injected in to LC system.  
No additional peaks were found in chromatogram & area under the 
peak comes within 2.0 % of RSD indicate the stability of NEPA in the 
sample solution. 
Degradation Kinetic Study 
For relatively unstable drug, systematic kinetic studies of the 
degradation of drugs using stability testing techniques are essential 
for the quality control. In this work, we report a kinetic investigation 
of NEPA in acid, alkaline and oxidative condition. Calculations have 
been based on the measurement of the concentration of the Drug 
remaining using the previously described HPLC-UV method. At the 
selected temperatures and time interval (Table 4), the acid and 
oxidative degradation followed zero order kinetic while alkaline 
degradation followed first order kinetics (Fig. 12). A regular 
decrease in the percentage of drug remaining with increasing time 
intervals was observed. From the slopes of the straight lines, it was 
possible to calculate the degradation rate constant (Kobs) and half-
life (t1/2
S. No. 
) of NEPA (Table 4). 
Table 3: Analytical Validation Parameters for the determination 
of NEPA using HPLC method 
Parameters NEPA 
1.  Detection wavelength (nm) 238 nm  
2.  Linearity range (µg mL-1 1-200 ) 








4.  Accuracy 99.914±0.060 
5.  Intraday Precision(%RSD) 0.5112 
6.  Interday Precision(%RSD) 1.1673 
7.  LOD (µg mL-1 0.3095 ) 
8.  LOQ(µg mL-1 0.9381 ) 







Fig. 12: (a) Zero order Kinetics Plot of NEPA in 0.01, 0.03 & 0.05 
N HCl, (b) First order Kinetic plot of NEPA in 0.5, 1.0 & 2.0 N 
NaOH (c): Zero order Kinetic plot of NEPA in 30% H2O2 (d): 
Zero order Kinetic plot of NEPA in 15% H2O2 (e): Zero order 
Kinetic plot of NEPA in 6% H2O2 . 
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Table 4: Kinetic Data - Degradation rate constants & half-lives for acid, base and oxidative degradation 
Stressor Temperature (0 Concentration (N/%) C) Regression equation R t2 1/2 
HCl RT 0.01 Y=-0.7961x + 95.651 0.9442 62.86 
0.03 Y=-1.0517x + 65.394 0.9717 47.54 
0.05 Y=-0.2473x + 12.081 0.9709 20.02 
NaOH RT 0.5 Y=-0.0134x + 2.2692 0.9611 51.71 
1.0 Y=-0.0348x + 2.6227 0.9506 22.35 
2.0 Y=-0.031x + 1.9935 0.9873 19.91 
H2O 40 2 30% Y=-12.99x + 110.95 0.9365 3.85 
50 Y=-7.23x + 89.95 0.9915 3.85 
60 Y=-29.36x + 116.5 0.9876 1.70 
40 15 Y=-6.043x + 104.32 0.9858 8.27 
50 Y=-3.969x + 86.047 0.9488 12.62 
60 Y=-4.231x + 84.209 0.9488 11.82 
40 6.0 Y=-4.84x + 104.74 0.9475 10.33 
50 Y=-4.22x + 99.96 0.9891 11.84 
60 Y=-4.74x + 103.26 0.9245 9.2  
 
CONCLUSION 
The proposed LC method presented the ability to separate 
Nepafenac from all its degradation products and therefore can be 
applied in stability testing of the commercially available formulation. 
Nepafenac was rapidly degraded in acidic & basic medium and in the 
presence of hydrogen peroxide too, while it was more stable in UV 
radiation and thermal conditions. The structure of degradation 
related impurities were determined. Kinetic studies shows the acid 
Hydrolysis & Oxidation showed zero-order kinetics & Basic 
Hydrolysis Showed first order kinetics. 
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